• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Acute antithrombotic treatment of ischemic stroke.
Abstract Antithrombotic medication is a cornerstone of acute ischemic stroke treatment and secondary prevention. The efficacy of thrombolysis with alteplase in acute stroke has been demonstrated in several clinical trials. This safe and costeffective therapy has transformed the practice of stroke care and has led to subsequent trials of other antithrombotic medications for treatment of ischemic stroke in the acute phase. These antithrombotics include thrombolytic, antiplatelet and anticoagulant agents. While, no other medication has yet demonstrated adequate efficacy, our current and evolving understanding of infa...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Alderazi YJ, Grotta JC Tags: Curr Vasc Pharmacol Source Type: research

Emerging agents for the treatment and prevention of stroke: progress in clinical trials
Expert Opin Investig Drugs. 2021 Sep 24. doi: 10.1080/13543784.2021.1985463. Online ahead of print.ABSTRACTINTRODUCTION: Recent years have witnessed unprecedented progress in stroke care, but unmet needs persist regarding the efficacy of acute treatment and secondary prevention. Novel approaches are being tested to enhance the efficacy of thrombolysis or provide neuroprotection in non-thrombolized patients.AREAS COVERED: The current review highlights pharmaceutical agents under evaluation in clinical trials concerning the acute, subacute, and chronic phase post-stroke. We examine the evidence in favor of tenecteplase as an...
Source: Expert Opinion on Investigational Drugs - September 24, 2021 Category: Drugs & Pharmacology Authors: Apostolos Safouris Georgios Magoufis Georgios Tsivgoulis Source Type: research

Thrombolytic Agents for Acute Ischaemic Stroke Treatment: the Past, Present and Future.
Abstract Despite advances in the diagnosis and treatment of acute ischaemic stroke in the past two decades, stroke has remained the third cause of mortality and the single leading cause of disability worldwide. The immediate goal of acute ischaemic stroke therapy is to salvage the ischaemic penumbra through recanalisation of the occluded cerebral blood vessel. This is currently achieved through thrombolytics, which are pharmacological agents that can break up a clot blocking the flow of blood. To date, the only approved thrombolytic for treatment of acute ischaemic stroke is recombinant tissue plasminogen activato...
Source: CNS and Neurological Disorders Drug Targets - February 4, 2013 Category: Drugs & Pharmacology Authors: Balami JS, Chen R, Sutherland BA, Buchan AM Tags: CNS Neurol Disord Drug Targets Source Type: research

Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: a Review.
Abstract Primary cardiac tumors are uncommon, with an autopsy frequency of 0.001%-0.28%: 75% of them are benign, and 50-75% of these are myxomas. Often the first neurological manifestations of a cardiac myxoma include transient ischemic attacks and ischemic strokes. Although thrombolytic therapy represents the gold standard for acute ischemic stroke treatment, its safety and effectiveness in stroke patients with myxoma is unknown. From the analysis of the literature on thrombolysis in ischemic stroke patients with myxoma we report clinical evidence supporting the use of thrombolytics, and the application of thromb...
Source: Current Drug Safety - January 10, 2014 Category: Drugs & Pharmacology Authors: Acampa M, Guideri F, Tassi R, D'Andrea P, Marotta G, Giudice GL, Martini G Tags: Curr Drug Saf Source Type: research

Investigational drugs for ischemic stroke: what's in the clinical development pipeline for acute phase and prevention?
Expert Opin Investig Drugs. 2022 Apr 29. doi: 10.1080/13543784.2022.2072725. Online ahead of print.ABSTRACTINTRODUCTION: Stroke is a leading cause of disability and mortality and its burden expected to increase. The only approved drug for acute ischemic stroke is the intravenous thrombolytic alteplase. The risk of bleeding complications is one of the reasons for the undertreatment of eligible patients. Numerous drugs are currently being developed to improve safety-efficacy.AREAS COVERED: We reviewed literature from January 1st, 2000, to 15th January 2022 for the development and testing of novel drugs with the aim of target...
Source: Expert Opinion on Investigational Drugs - April 29, 2022 Category: Drugs & Pharmacology Authors: Maria Giulia Mosconi Maurizio Paciaroni Walter Ageno Source Type: research

Conversion From Intravenous Alteplase to Tenecteplase for Treatment of Acute Ischemic Stroke Across a Large Community Hospital Health System
CONCLUSION AND RELEVANCE: Conversion from alteplase to tenecteplase can be safely and effectively achieved at a large community hospital health system with differing levels of stroke certification. There were also additional cost savings and practical advantages including workflow benefits.PMID:36688289 | DOI:10.1177/10600280221149409
Source: The Annals of Pharmacotherapy - January 23, 2023 Category: Drugs & Pharmacology Authors: Erika Dittmar Thomas Wolfel Lourdes Menendez Jessilyn Pozo Maygret Ramirez Starlie C Belnap Felipe De Los Rios La Rosa Source Type: research

Pages: 1  2  3